RVPH Company Report

Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $4.0 million, or $0.06 per share, for the three months ended September 30, 2025, an improvement compared to a net loss of $8.4 million, or $0.25 per share, for the same period in 2024.
As of September 30, 2025, the company's cash and cash equivalents totaled approximately $13.2 million.
A pre-NDA meeting with the FDA to discuss brilaroxazine's path to approval for schizophrenia is planned for Q4 2025, with a potential NDA submission targeted for Q2 2026.
The company also announced the granting of a European patent covering the use of brilaroxazine for the treatment of pulmonary fibrosis, successfully completed the Phase 3 RECOVER open-label extension 1-year study for schizophrenia, and raised $9.0 million in gross proceeds from a public equity offering.

Nov 13, 2025, 9:19 PM

Reviva Pharmaceuticals Holdings Announces European Patent Grant for Brilaroxazine in Pulmonary Fibrosis

RVPH

New Projects/Investments

Reviva Pharmaceuticals Holdings announced that the European Patent Office (EPO) granted European Patent 3749324, covering the use of brilaroxazine for treating pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF).
This patent strengthens the company's intellectual property portfolio, adding to existing protection for brilaroxazine in key markets such as the United States, China, and Japan.
Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in pulmonary fibrosis and has received Orphan Drug Designation from the U.S. FDA for both IPF and pulmonary arterial hypertension (PAH).
The company plans to expand brilaroxazine's clinical development from schizophrenia into additional high-value indications, leveraging its well-tolerated profile observed in trials.

Nov 10, 2025, 1:00 PM

Revival Pharmaceuticals Discusses Biloroxazine Clinical Progress and Regulatory Strategy

RVPH

New Projects/Investments

Guidance Update

Revival Pharmaceuticals (RVPH) is a late-stage biopharma company focused on developing Biloroxazine for schizophrenia, currently in Phase 3 development, with potential for other neuropsychiatric conditions.
Clinical trials involving over 900 patients have demonstrated Biloroxazine's robust efficacy, particularly for negative symptoms, and durable efficacy with a low relapse rate. The Phase 3 RECOVER one study showed a 10 separation from placebo in PANSS total score.
The drug exhibits a favorable safety profile, with hardly any motor side effects (less than 1% in Phase 3) and a low discontinuation rate of 35% in the open-label study, compared to 50-80% for other antipsychotics.
Revival Pharmaceuticals anticipates a Type C meeting with the FDA in December 2025 (Q4 2025) to discuss pre-NDA feedback, with a potential for early NDA filing in Q2 2026 and drug approval in early 2027.

Sep 30, 2025, 2:15 PM

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of Public Offering

RVPH

Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced the pricing of a public offering on September 18, 2025, for aggregate gross proceeds of approximately $9 million.
The offering includes 27,000,000 shares of common stock (or equivalents) along with Series E and Series F warrants to purchase up to 27,000,000 shares each, at a combined offering price of $0.335 per share and accompanying warrants.
Both Series E and Series F warrants have an exercise price of $0.335 per share; Series E warrants expire in five years, and Series F warrants expire in 12 months from the issuance date.
The closing of the offering is expected around September 22, 2025, with net proceeds of approximately $8.1 million intended for research and development activities, working capital, and general corporate purposes.

Sep 19, 2025, 9:27 PM

Get instant answers from SEC filings, earnings calls & more

Company not found (RVPH)